Breaking News
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

FDA Approves Lupin's Generic Lexapro Tabs In U.S.

9/13/2012 10:24 AM ET

India's Lupin Pharmaceuticals Inc. (500257: Quote,LUPIN: Quote) on Thursday said it won the final approval from U.S. Food and Drugs Administration, or FDA, to market its anti-depressant drug, escitalopram tablets, a generic version of Forest Laboratories' lexapro tablets in the U.S.

In addition, Lupin said it was the only Asian company to achieve the distinction of being the fifth largest generics player in the U.S.

Lupin's Escitalopram Tablets will be used to treat adults and children between 12-17 years and who suffer from major depressive and anxiety disorders in adults.

Click here to receive FREE breaking news email alerts for Lupin Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A second union representing immigration enforcement officers has expressed opposition to the Senate version of comprehensive immigration reform legislation, arguing that the bill fails to address the "insurmountable bureaucracy" at the agency that oversees lawful immigration to the U.S. Stocks are turning in a lackluster performance in early trading on Monday after showing a strong move to the upside last week. The major averages are showing only modest moves, lingering near the unchanged line. The major averages are currently turning in a mixed performance, with the Nasdaq just above the unchanged line. Thailand lowered its full-year growth outlook after weaker domestic demand and exports weighed on economic activity in the first three months of the year. Gross domestic product expanded 5.3 percent year-on-year in the first quarter of 2013 compared to an upwardly revised 19.1 percent growth in the fourth quarter of 2012, the National Economic and Social Development Board (NESDB) said Monday.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.